Copyright
©2013 Baishideng Publishing Group Co.
World J Ophthalmol. Aug 12, 2013; 3(3): 20-31
Published online Aug 12, 2013. doi: 10.5318/wjo.v3.i3.20
Published online Aug 12, 2013. doi: 10.5318/wjo.v3.i3.20
Table 3 Phakic intraocular lenses for keratoconus studies
Ref. | Criteria | Lens | Preoperative | Postoperative | P-value |
Leccisotti et al[12] | 12 eyes. KC I y II | Angular supported, spherical | Sphere -10.23 ± 2.85 D | Sph 0.46 ± 0.45 D | 0.002 |
Cyl -2.79 ± 1.11 D | Cyl -2.35 ± 1 D | ||||
CDVA 0.13 ± 0.17 | UCVA 0.44 ± 0.8 | ||||
CDVA 0.03 ± 0.05 | |||||
Alfonso et al[14] | 25 eyes | Posterior chamber, spherical | Sph -8.54 ± 4.15 D | Sph 0.0 ± 0.25 D | < 0.05 |
Cyl -1.24 ± 1.19 D | Cyl -0.45 ± 0.73 D | ||||
CDVA 0.13 ± 0.15 | SE -0.32 ± 0.55 D | ||||
UCVA 0.17 ± 0.19 | |||||
CDVA 0.12±0.12 | |||||
Venter et al[15] | 18 eyes | Iris supported, toric/spherical | Sph -4.64 ± 2.74 D | SE -0.46 ± 0.6 D | < 0.05 |
Cyl -3.07 ± 2.04 D | UDVA ≥ 0.2 en 94% | ||||
CDVA ≥0.5 | |||||
Alfonso et al[16] | 30 eyes | Posterior chamber, toric | SE -5.38 ± 3.26 D | SE -0.08 ± 0.37 D | |
Cyl -3.48 ± 1.24 D | Cyl 0.41 ± 0.61 D | ||||
UDVA 0.8 logMar | UDVA 0.10 logMar | ||||
CDVA 0.10 | CDVA 0.10 | ||||
Kamiya et al[17] | 27 eyes, mild KC | Posterior chamber, tori | SE -10.11 ± 2.46 D | SE 0.00 ± 0.35 D | |
Cyl -3.03 ± 1.58 D | UCVA -0.09 ± 0.16 | ||||
UCVA 1.51 ± 0.2 | CDVA -0.15 ± 0.09 | ||||
CDVA -0.11 ± 0.08 | |||||
Sedaghat et al[18] | 16 eyes, | Anterior chamber, iris supported | Sph -12.5 ± 4.61 D | Sph -0.03±1.81 D | < 0.0001 |
Cyl 2.95 ± 4.06 D | Cyl 2.08 ± 1.04 D | ||||
SE -13.9 ± 4.61 D | UDVA 0.15 ± 0.13 | ||||
UDVA CF | CDVA 0.11 ± 0.1 | ||||
CDVA 0.21 ± 0.14 | |||||
Kato et al[19] | 36 eyes | Iris supported, toric, spherical | SE -8.38 ± 3.42 D | SE -0.42 ± 0.89 D | |
Cyl 2.44 ± 2.25 D | Cyl 0.62 ± 0.69 D | ||||
UDVA 1.39 ± 0.42 | UDVA 0.02 ± 0.21 | ||||
Hashemian et al[20] | 22 eyes | ICL toric | SE -4.98 ± 2.63 D | SE -0.33 ± 0.51 D | |
Cyl -2.77 ± 0.99 D | Cyl -1.23 ± 0.65 D | ||||
UDVA 0.63 ± 0.2 dec. | UDVA 0. 85 ± 0.21 dec. | ||||
Combined procedures | |||||
Moshirfar et al[21] | 19 eyes | Intacs/verisyse, sequential vs simultaneous | SE -12.38 ± 4.2 D | SE -1.2 ± 1.15 D | No difference regarding sequential vs simultaneous |
Cyl 3.3 ± 1.8 D | Cyl 2.06 ± 1.1 D | ||||
UCVA 2.025 ± 0.32 | UCVA 0.465 ± 0.18 | ||||
CDVA 0.34 ± 0.22 | CDVA 0.15 ± 0.09 | ||||
Izquierdo et al[22] | 11 eyes Progressive KC I and II | Crosslinking/verisyse | Sph -5.7 D | Sph -0.27 D | < 0.05 |
Cyl -1.45 D | Cyl -0.9 D | ||||
SE -6.42 D | SE -0.72 D | ||||
UDVA 1.4 ± 0.4 | UDVA 0.16 ± 0.06 | ||||
CDVA 0.14 ± 0.06 | CDVA 0.04 ± 0.05 | ||||
Alfonso et al[23] | 40 eyes | Keraring/ICL | SE -9.65 ± 6.9 D | SE -1.2 ± 1.3 D | |
UDVA 1.0 | UDVA 0.3 | ||||
CDVA 0.3 | CDVA 0.18 | ||||
Güell et al[24] | 17 eyes Progressive KC I and II | Crosslinking and toric artiflex/artisan | SE -6.99 ± 3.2 D | SE -0.22 ± 0.33 D | |
Cyl -3.54 ± 1.38 D | Cyl -0.62 ± 0.39 D | ||||
UDVA < 1 | 0.17 ± 013 | ||||
CDVA 0.1 ± 0.09 | CDVA 0.10 ± 0.09 | ||||
Navas et al[25] | 11 eyes KC I-IV | ICRS and toric and spherical ICL | Sph -9.04 ± 6.03 D | Sph -0.06 ± 0.46 D | < 0.01 |
Cyl -2.95 ± 1.35 D | Cyl -1.22 ± 0.65 D | ||||
SE -10.52 ± 5.88 D | SE -0.68 ± 0.45 D | ||||
UDVA 1.31 ± 0.37 | UDVA 0.14 ± 0.04 | ||||
CDVA 0.289 ± 0.14 | CDVA 0.16 ± 0.08 |
- Citation: Jaimes M, Ramirez-Miranda A, Graue-Hernández EO, Navas A. Keratoconus therapeutics advances. World J Ophthalmol 2013; 3(3): 20-31
- URL: https://www.wjgnet.com/2218-6239/full/v3/i3/20.htm
- DOI: https://dx.doi.org/10.5318/wjo.v3.i3.20